Lactobacillus paracasei (K71 / LP33) for Allergic Rhinitis
Verdict: Disputed
Across 6 PubMed studies, the evidence for Lactobacillus paracasei (K71 / LP33) in Allergic Rhinitis grades Tier C — weak evidence. High-quality studies disagree — the evidence is genuinely mixed.
C 🟠 C Weak Evidence Disputed
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.56
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Disputed
Confidence
67%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.558
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
- tier_strict_requirement_check — | B→C 因 scope.conflation_risk=true 且 L11 獨評較低 (B7-2 tier cap)
- detect_disputes — 偵測到 1 個 hard + 1 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (6)L2 · primary research & systematic reviews
Efficacy and safety of the probiotic Lactobacillus paracasei LP-33 in allergic rhinitis (GA2LEN Study)
Finding: RQLQ global score decreased significantly more in LP-33 group than placebo (P=0.0255); ocular symptoms significantly improved (P=0.0029); however nasal total symptom score showed NO significant difference (P=0.1288).
View on PubMed Treatment of perennial allergic rhinitis with lactic acid bacteria (Wang et al., LP-33)
Finding: QoL frequency score improved significantly more with LP-33 vs placebo (-16.02 vs -7.27, p=0.037); bother score (-16.35 vs -6.20, p=0.022); no severe adverse effects.
View on PubMed Evaluation of L. paracasei (HF.A00232) in children with perennial allergic rhinitis: a 12-week RCT (Lin et al.)
Finding: LP group had significantly lower PRQLQ after levocetirizine withdrawal (p<0.01); improvements in sneezing (p=0.005), itchy nose (p=0.040), swollen eyes (p=0.038); BUT no significant difference in NTSS/TSS/TTSS/ETSS or cytokines.
View on PubMed RCT of L. paracasei K71 intake on salivary sIgA release
Finding: Salivary sIgA increase significantly higher in K71 vs placebo at wk 8 (105.5 vs 52.7 μg/min, p=0.047); K71 previously shown to alleviate atopic dermatitis but this trial did NOT measure AR symptoms.
View on PubMed Effects of Probiotics on Allergic Rhinitis: A Systematic Review and Meta-Analysis of RCTs
Finding: Slight improvement on some clinical/immunological measures but strain-dependent; L. paracasei LP-33 nasal symptom SMD -1.61 (95% CI -4.67, 1.45) — NOT statistically significant.
View on PubMed Do probiotics have a role in the treatment of allergic rhinitis? A comprehensive systematic review and meta-analysis
Finding: 17/22 trials showed clinical benefit; all 5 L. paracasei trials showed clinically significant improvement vs placebo; LP-33 showed homogeneity in nasal QoL outcomes; seasonal AR particularly responsive.
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L5a NIH Office of Dietary Supplements
Cautious
A review of 23 studies (1,919 participants) in which probiotics were tested for treating allergic rhinitis found some evidence that they may be helpful for improving symptoms and quality of life... because the studies tested different probiotics and measured different effects, no recommendations about the use of probiotics could be made. source↗
L5e Specialty Society (condition-mapped)
Cautious